AsymBio, a China-based global Contract Development and Manufacturing Organisation (CDMO) and a subsidiary of Asymchem Group (SZ:002821, HK:6821), announced on Monday that it has commenced commercial production at its Shanghai Fengxian Commercial Manufacturing Base.

This expands AsymBio's integrated, end-to-end biologics CDMO services.

Coving 130,000 square metres, the Fengxian facility is designed to provide flexible, scalable support across all clinical phases, enabling tailored CDMO solutions from early development through commercial production. It will produce an expanded range of next-generation biotherapeutics, including ADCs, dual-payload ADCs, RDCs, APCs, PDCs, AOCs, and monoclonal, bispecific, and multi-specific antibodies and recombinant proteins.

Phase IA is dedicated to antibody manufacturing, featuring single-use bioreactors (200L, 500L, and 2000L) with a total drug substance capacity of 66,000 litres. A 20-square-metre lyophiliser supports production of up to one million vials of lyophilised antibody drug product annually.

Phase IB is focused on bioconjugate manufacturing, equipped with 200L and 500L reactors for all clinical phases. The drug product area includes clinical-scale lines (10-square-metre and 15-square-metre lyophilisers) and commercial-scale lines (two 20-square-metre lyophilisers), enabling annual output of up to two million vials.